Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo

Schwab, Carlton

140
Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo

Sunday, March 29, 2015: 3:05 PM

Salon C-D (Hilton Chicago)

C. L. Schwab¹, D. P. English¹, J. D. Black¹, S. Lopez², S. Bellone¹, D. M. Roque³, E. S. Ratner¹, D. A. Silasi¹, M. Azodi¹, T. J. Rutherford¹, P. E. Schwartz¹ and A. Santin¹
¹Yale University School of Medicine, New Haven, CT, ²University Campus Bio-Medico of Rome, Rome, Italy, ³University of Maryland School of Medicine, Baltimore, MD

2015 Annual Meeting on Women's Cancer®

March 26 - 31, 2015

Navigation

140
Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo

140 Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo

140
Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo